Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04336943
Title Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements Yes
Sponsors University of Washington
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST